prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients流行相关的二磷酸盐的下颚骨坏死多发性骨髓瘤患者.pdfVIP

Walter et al. Head Face Medicine 2010, 6:11 /content/6/1/11 HEAD FACE MEDICINE R E S E A R C H Open Access Research Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients 1 1 2 3 3 1 Christian Walter* , Bilal Al-Nawas , Norbert Frickhofen , Heinold Gamm , Joachim Beck , Laura Reinsch , 1 1,4 1 Christina Blum , Knut A Grötz and Wilfried Wagner Abstract Background: Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is an adverse effect of bisphosphonate treatment with varying reported incidence rates. Methods: In two neighboring German cities, prevalence and additional factors of the development of BP-ONJ in multiple myeloma patients with bisphosphonates therapy were recorded using a retrospective (RS) and cross-sectional study (CSS) design. For the RS, all patients treated from Jan. 2000 - Feb. 2006 were contacted by letter. In the CSS, all patients treated from Oct. 2006 - Mar. 2008 had a physical and dental examination. Additionally, a literature review was conducted to evaluate all articles reporting on BP-ONJ prevalence. PubMed search terms were: bisphosphonat, diphosphonate, osteonecrosis, prevalence and incidence. Results: In the RS, data from 81 of 161 patients could be obtained; four patients (4.9%) developed BP-ONJ. In the CSS, 16 of 78 patients (20.5%) developed BP-ONJ. All patients with BP-ONJ had received zoledronate; 12 of these had had additional bisphosphonates. All except one had an additional trigger factor (tooth extraction [n = 14], dental surgical proced